Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Rafael Rosell
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Procedures
Chemicals & Drugs
Concepts & Ideas
Physiology
Genes & Molecular Sequences
Sign-in to see full Profile
Network (preview)
49
Taron, Miquel
33
Camps, Carlos
27
Felip, Enriqueta
27
Sanchez, Jose Javier
22
Alberola, Vicente
22
Font, Albert
20
Barnadas, Agustí
18
Massuti, Bartomeu
18
Monzó, Mariano
18
Sánchez, José Javier
17
Isla, Dolores
15
Sanchez, Jose Miguel
12
Reguart, Noemi
12
Moran, Teresa
12
Mendez, Pedro
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Rafael Rosell (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Provencio Mariano; Camps Carlos; Alberola Vicente; Massutti Bertomeu; Viñolas Nuria; Isla Dolores; Dómine Manuel; Millán Isabel; Cobo Manuel; Rosell Rafael
Lung cancer and treatment in elderly patients: the Achilles Study.
Lung cancer (Amsterdam, Netherlands) 2009;66(1):103-6.
-
2009: Rosell Rafael; Moran Teresa; Queralt Cristina; Porta Rut; Cardenal Felipe; Camps Carlos; Majem Margarita; Lopez-Vivanco Guillermo; Isla Dolores; Provencio Mariano; Insa Amelia; Massuti Bartomeu; Gonzalez-Larriba Jose Luis; Paz-Ares Luis; Bover Isabel; Garcia-Campelo Rosario; Moreno Miguel Angel; Catot Silvia; Rolfo Christian; Reguart Noemi; Palmero Ramon; Sánchez José Miguel; Bastus Roman; Mayo Clara; Bertran-Alamillo Jordi; Molina Miguel Angel; Sanchez Jose Javier; Taron Miquel;
Screening for epidermal growth factor receptor mutations in lung cancer.
The New England journal of medicine 2009;361(10):958-67.
-
2009: Marco I; Rosell R; Cabezón O; Beneria M; Mentaberre G; Casas E; Hurtado A; López-Olvera J R; Lavín S
Serologic and virologic investigations into pestivirus infection in wild and domestic ruminants in the Pyrenees (NE Spain).
Research in veterinary science 2009;87(1):149-53.
-
2009: Garrido Pilar; Rosell Rafael; Massutí Bartomeu; Cardenal Felipe; Alberola Vicente; Dómine Manuel; Maeztu Inmaculada; Ramos Alfredo; Arellano Antonio;
Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy.
Clinical lung cancer 2009;10(3):180-6.
-
2009: Rosell Rafael; Bertran-Alamillo Jordi; Molina Miguel Angel; Taron Miquel
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors.
Future oncology (London, England) 2009;5(3):305-8.
-
2009: Bartolucci Roberta; Wei Jia; Sanchez Jose Javier; Perez-Roca Laia; Chaib Imane; Puma Francesco; Farabi Raffaele; Mendez Pedro; Roila Fausto; Okamoto Tatsuro; Taron Miquel; Rosell Rafael
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
Clinical lung cancer 2009;10(1):47-52.
-
2009: Rosell Rafael; Perez-Roca Laia; Sanchez Jose Javier; Cobo Manuel; Moran Teresa; Chaib Imane; Provencio Mariano; Domine Manuel; Sala Maria Angeles; Jimenez Ulpiano; Diz Pilar; Barneto Isidoro; Macias Jose Antonio; de Las Peñas Ramon; Catot Silvia; Isla Dolores; Sanchez Jose Miguel; Ibeas Rafael; Lopez-Vivanco Guillermo; Oramas Juana; Mendez Pedro; Reguart Noemi; Blanco Remei; Taron Miquel
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
PloS one 2009;4(5):e5133.
-
2008: Molina-Vila Miguel A; Bertran-Alamillo Jordi; Reguart Noemí; Taron Miquel; Castellà Eva; Llatjós Mariona; Costa Carlota; Mayo Clara; Pradas Anna; Queralt Cristina; Botia Mónica; Pérez-Cano María; Carrasco Esther; Tomàs Mireia; Mate Jose Luis; Moran Teresa; Rosell Rafael
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(11):1224-35.
-
2008: Font Albert; Salazar Ramon; Maurel Joan; Taron Miquel; Ramirez Jose Luis; Tabernero Josep; Gallego Rosa; Casado Esther; Manzano Jose Luis; Carcereny Enric; Guix Marta; Fernández-Llamazares Jaume; Rosell Rafael
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Cancer chemotherapy and pharmacology 2008;62(6):1075-83.
-
2008: Raz Dan J; Ray M Roshni; Kim Jae Y; He Biao; Taron Miquel; Skrzypski Marcin; Segal Mark; Gandara David R; Rosell Rafael; Jablons David M
A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5565-70.
-
2008: Skrzypski Marcin; Jassem Ewa; Taron Miquel; Sanchez Jose Javier; Mendez Pedro; Rzyman Witold; Gulida Grazyna; Raz Dan; Jablons David; Provencio Mariano; Massuti Bartomeu; Chaib Imane; Perez-Roca Laia; Jassem Jacek; Rosell Rafael
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4794-9.
-
2008: Pignon Jean-Pierre; Tribodet Hélène; Scagliotti Giorgio V; Douillard Jean-Yves; Shepherd Frances A; Stephens Richard J; Dunant Ariane; Torri Valter; Rosell Rafael; Seymour Lesley; Spiro Stephen G; Rolland Estelle; Fossati Roldano; Aubert Delphine; Ding Keyue; Waller David; Le Chevalier Thierry;
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3552-9.
-
2008: Sirera Rafael; Gil Mireia; Blasco Ana; Cabrera Andrea; Safont María José; Iranzo Vega; Cayuela Diego; Rosell Rafael; Camps Carlos
Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2008;61(1):104-8.
-
2008: Rosell Rafael; de Las Peñas Ramon; Balaña Carme; Santarpia Mariacarmela; Salazar Fernanda; de Aguirre Itziar; Reguart Noemi; Villa Salvador; Wei Jia; Ramirez Jose Luis; Molina Miguel Angel; Ramon y Cajal Santiago; Jablons David; Taron Miquel
Translational research in glioblastoma multiforme: molecular criteria for patient selection.
Future oncology (London, England) 2008;4(2):219-28.
-
2008: Rosell R; Robinet G; Szczesna A; Ramlau R; Constenla M; Mennecier B C; Pfeifer W; O'Byrne K J; Welte T; Kolb R; Pirker R; Chemaissani A; Perol M; Ranson M R; Ellis P A; Pilz K; Reck M
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):362-9.
-
2008: Boukovinas Ioannis; Papadaki Chara; Mendez Pedro; Taron Miquel; Mavroudis Dimitris; Koutsopoulos Anastasios; Sanchez-Ronco Maria; Sanchez Jose Javier; Trypaki Maria; Staphopoulos Eustathios; Georgoulias Vassilis; Rosell Rafael; Souglakos John
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
PloS one 2008;3(11):e3695.
-
2007: Balaña C; Capellades J; Teixidor P; Roussos I; Ballester R; Cuello M; Arellano A; Florensa R; Rosell R
Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(12):797-803.
-
2007: Rosell Rafael; Mendez Pedro; Isla Dolores; Taron Miquel
Platinum resistance related to a functional NER pathway.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(12):1063-6.
-
2007: Garrido Pilar; González-Larriba José Luis; Insa Amelia; Provencio Mariano; Torres Antonio; Isla Dolores; Sanchez José Miguel; Cardenal Felipe; Domine Manuel; Barcelo Jose Ramon; Tarrazona Vicente; Varela Andres; Aguilo Rafael; Astudillo Julio; Muguruza Ignacio; Artal Angel; Hernando-Trancho Florentino; Massuti Bartomeu; Sanchez-Ronco Maria; Rosell Rafael
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4736-42.
-
2007: Ramírez de Molina Ana; Sarmentero-Estrada Jacinto; Belda-Iniesta Cristóbal; Tarón Miquel; Ramírez de Molina Victor; Cejas Paloma; Skrzypski Marcin; Gallego-Ortega David; de Castro Javier; Casado Enrique; García-Cabezas Miguel Angel; Sánchez Jose Javier; Nistal Manuel; Rosell Rafael; González-Barón Manuel; Lacal Juan Carlos
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.
The lancet oncology 2007;8(10):889-97.
-
2007: Felip Enriqueta; Santarpia Mariacarmela; Rosell Rafael
Emerging drugs for non-small-cell lung cancer.
Expert opinion on emerging drugs 2007;12(3):449-60.
-
2007: Rosell Rafael; Felip Enriqueta; Paz-Ares Luis
How could pharmacogenomics help improve patient survival?
Lung cancer (Amsterdam, Netherlands) 2007;57 Suppl 2():S35-41.
-
2007: Cobo Manuel; Isla Dolores; Massuti Bartomeu; Montes Ana; Sanchez Jose Miguel; Provencio Mariano; Viñolas Nuria; Paz-Ares Luis; Lopez-Vivanco Guillermo; Muñoz Miguel Angel; Felip Enriqueta; Alberola Vicente; Camps Carlos; Domine Manuel; Sanchez Jose Javier; Sanchez-Ronco Maria; Danenberg Kathleen; Taron Miquel; Gandara David; Rosell Rafael
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2747-54.
-
2007: Camps Carlos; Sirera Rafael; Iranzo Vega; Tarón Miquel; Rosell Rafael
Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy.
Clinical lung cancer 2007;8(6):369-75.
-
2007: Font A; Arellano A; Fernández-Llamazares J; Casas D; Boix J; Cardenal J; Margelí M; Manzano J L; Abad A; Rosell R
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(3):177-82.
-
2007: Bellmunt J; Paz-Ares L; Cuello M; Cecere F L; Albiol S; Guillem V; Gallardo E; Carles J; Mendez P; de la Cruz J J; Taron M; Rosell R; Baselga J;
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):522-8.
-
2007: Rosell Rafael; Skrzypski Marcin; Jassem Ewa; Taron Miquel; Bartolucci Roberta; Sanchez Jose Javier; Mendez Pedro; Chaib Imane; Perez-Roca Laia; Szymanowska Amelia; Rzyman Witold; Puma Francesco; Kobierska-Gulida Grazyna; Farabi Raffaele; Jassem Jacek
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
PloS one 2007;2(11):e1129.
-
2006: Rosell Rafael; Taron Miquel; Reguart Noemi; Isla Dolores; Moran Teresa
Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7222-31.
-
2006: Rosell R; Moran T; Fernanda Salazar M; Mendez P; De Aguirre I; Ramirez J-L; Isla D; Cobo M; Camps C; Lopez-Vivanco G; Alberola V; Taron M
The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.
Revue des maladies respiratoires 2006;23(5 Pt 3):16S131-16S136.
-
2006: Camps Carlos; Sirera Rafael; Bremnes Roy M; Ródenas Vanessa; Blasco Ana; Safont María José; Garde Javier; Juarez Asuncion; Caballero Cristina; Sanchez Josie Javier; Taron Miquel; Rosell Rafael
Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer.
Anticancer research 2006;26(6C):4905-9.
-
2006: Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Usefulness of predictive tests for cancer treatment.
Bulletin du cancer 2006;93(8):E101-8.
-
2006: Rosell Rafael; Cecere Fabiana; Santarpia Mariacarmela; Reguart Noemi; Taron Miquel
Predicting the outcome of chemotherapy for lung cancer.
Current opinion in pharmacology 2006;6(4):323-31.
-
2006: Rosell R; Cobo M; Isla D; Camps C; Massuti B
Pharmacogenomics and gemcitabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v13-16.
-
2006: de las Peñas R; Sanchez-Ronco M; Alberola V; Taron M; Camps C; Garcia-Carbonero R; Massuti B; Queralt C; Botia M; Garcia-Gomez R; Isla D; Cobo M; Santarpia M; Cecere F; Mendez P; Sanchez J J; Rosell R;
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):668-75.
-
2006: Felip Enriqueta; Rosell Rafael
Clinical experience with erlotinib in non-small-cell lung cancer.
Drugs of today (Barcelona, Spain : 1998) 2006;42(3):147-56.
-
2006: Rosell Rafael; Cuello Mauricio; Cecere Fabiana; Santarpia Mariacarmela; Reguart Noemi; Felip Enriqueta; Taron Miquel
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Current opinion in oncology 2006;18(2):135-43.
-
2006: Camps C; Massuti B; Jiménez A; Maestu I; Gómez R García; Isla D; González J L; Almenar D; Blasco A; Rosell R; Carrato A; Viñolas N; Batista N; Girón C García; Galán A; López M; Blanco R; Provencio M; Diz P; Felip E;
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):467-72.
-
2006: Santarpia Mariacarmela; Altavilla Giuseppe; Salazar Fernanda; Tarón Miquel; Rosell Rafael
From the bench to the bed: individualizing treatment in non-small-cell lung cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2006;8(2):71-6.
-
2006: Rosell Rafael; Cecere Fabiana; Cognetti Francesco; Cuello Mauricio; Sanchez Jose Miguel; Taron Miquel; Reguart Noemi; Jablons David
Future directions in the second-line treatment of non-small cell lung cancer.
Seminars in oncology 2006;33(1 Suppl 1):S45-51.
-
2005: Rosell Rafael; Cobo Manuel; Isla Dolores; Sanchez Jose Miguel; Taron Miquel; Altavilla Giuseppe; Santarpia Mariacarmela; Moran Teresa; Catot Silvia; Etxaniz Olatz
Applications of genomics in NSCLC.
Lung cancer (Amsterdam, Netherlands) 2005;50 Suppl 2():S33-40.
-
2005: Ramirez José Luis; Rosell Rafael; Taron Miquel; Sanchez-Ronco Maria; Alberola Vicente; de Las Peñas Ramon; Sanchez José Miguel; Moran Teresa; Camps Carlos; Massuti Bartomeu; Sanchez José Javier; Salazar Fernanda; Catot Silvia;
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9105-12.
-
2005: Camps Carlos; Sirera Rafael; Bremnes Roy; Blasco Ana; Sancho Eva; Bayo Pilar; Safont Maria Jose; Sánchez José Javier; Tarón Miquel; Rosell Rafael
Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
Lung cancer (Amsterdam, Netherlands) 2005;50(3):339-46.
-
2005: Rosell Rafael; Ichinose Yukito; Taron Miquel; Sarries Carme; Queralt Cristina; Mendez Pedro; Sanchez Jose Miguel; Nishiyama Ken-Ichi; Moran Teresa; Cirauqui Beatriz; Mate Jose Luis; Besse Benjamin; Reguart Noemi; Perez Maria; Sanchez Jose Javier
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;50(1):25-33.
-
2005: Taron Miguel; Ichinose Yukito; Rosell Rafael; Mok Tony; Massuti Bartomeu; Zamora Lurdes; Mate Jose Luis; Manegold Christian; Ono Mayumi; Queralt Cristina; Jahan Thierry; Sanchez Jose Javier; Sanchez-Ronco Maria; Hsue Victor; Jablons David; Sanchez Jose Miguel; Moran Teresa
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5878-85.
-
2005: Cortes-Funes H; Gomez C; Rosell R; Valero P; Garcia-Giron C; Velasco A; Izquierdo A; Diz P; Camps C; Castellanos D; Alberola V; Cardenal F; Gonzalez-Larriba J L; Vieitez J M; Maeztu I; Sanchez J J; Queralt C; Mayo C; Mendez P; Moran T; Taron M
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):1081-6.
-
2005: Rosell Rafael; Felip Enriqueta; Reguart Noemí; Moran Teresa
Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.
Future oncology (London, England) 2005;1(3):319-22.
-
2005: Camps C; Felip E; Sanchez J M; Massuti B; Artal A; Paz-Ares L; Carrato A; Alberola V; Blasco A; Baselga J; Astier L; Voi M; Rosell R;
Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(4):597-601.
-
2005: Felip Enriqueta; Taron Miquel; Rosell Rafael; Mendez Pedro; Queralt Cristina; Ronco Maria Sanchez; Sanchez Jose Javier; Sanchez Jose Miguel; Maestre Jose; Majo Joaquim
Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.
Clinical lung cancer 2005;6(5):299-303.
-
2005: Font A; Murias A; Arroyo F R García; Martin C; Areal J; Sanchez J J; Santiago J A; Constenla M; Saladie J M; Rosell R
Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(3):419-24.
-
2005: Le Chevalier T; Scagliotti G; Natale R; Danson S; Rosell R; Stahel R; Thomas P; Rudd R M; Vansteenkiste J; Thatcher N; Manegold C; Pujol J-L; van Zandwijk N; Gridelli C; van Meerbeeck J P; Crino L; Brown A; Fitzgerald P; Aristides M; Schiller J H
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
Lung cancer (Amsterdam, Netherlands) 2005;47(1):69-80.
-
2004: Rosell Rafael; Taron Miquel; Sanchez Jose Miguel; Moran Teresa; Reguart Noemi; Besse Benjamin; Isla Dolores; Massuti Bartomeu; Alberola Vicente; Sanchez Jose Javier
The promise of pharmacogenomics: gemcitabine and pemetrexed.
Oncology (Williston Park, N.Y.) 2004;18(13 Suppl 8):70-6.
-
2004: Artal-Cortés Angel; Gomez-Codina Jose; Gonzalez-Larriba Jose Luis; Barneto Isidoro; Carrato Alfredo; Isla Dolores; Camps Carlos; Garcia-Giron Carlos; Font Albert; Meana Alfredo; Lomas Maria; Vadell Catalina; Arrivi Antonio; Alonso Carmen; Maestu Immaculada; Campbell Joaquin; Rosell Rafael
Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.
Clinical lung cancer 2004;6(3):175-83.
-
2004: Rosell R; Felip E; Garcia-Campelo R; Balaña C
The biology of non-small-cell lung cancer: identifying new targets for rational therapy.
Lung cancer (Amsterdam, Netherlands) 2004;46(2):135-48.
-
2004: Taron Miquel; Rosell Rafael; Felip Enriqueta; Mendez Pedro; Souglakos John; Ronco Maria Sanchez; Queralt Cristina; Majo Joaquim; Sanchez Jose Miguel; Sanchez Jose Javier; Maestre Jose
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Human molecular genetics 2004;13(20):2443-9.
-
2004: Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez J J; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1194-203.
-
2004: Rosell Rafael; Sanchez Jose Miguel; Taron Miquel; Moran Teresa; Ciuraqui Beatriz; Canela Mercedes; Felip Enriqueta; Massuti Bartomeu; Camps Carlos
Pemetrexed in previously treated non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2004;18(8 Suppl 5):63-71.
-
2004: Rosell Rafael; Felip Enriqueta; Taron Miquel; Majo Joaquim; Mendez Pedro; Sanchez-Ronco Maria; Queralt Cristina; Sanchez Jose Javier; Maestre Jose
Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4215s-4219s.
-
2004: Alberola Vicente; Sarries Carme; Rosell Rafael; Taron Miquel; de las Peñas Ramon; Camps Carlos; Massuti Bartomeu; Insa Amelia; Garcia-Gomez Ramon; Isla Dolores; Artal Angel; Muñoz Miguel Angel; Cobo Manuel; Bover Isabel; Gonzalez-Larria Jose Luis; Terrasa Josefa; Almenar Daniel; Barcelo Ramon; Diz Pilar; Sanchez-Ronco Maria; Sanchez Jose Javier
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
Clinical lung cancer 2004;5(6):360-5.
-
2004: Rico-Villademoros Fernando; Hernando Teresa; Sanz Juan-Luis; López-Alonso Antonio; Salamanca Oscar; Camps Carlos; Rosell Rafael
The role of the clinical research coordinator--data manager--in oncology clinical trials.
BMC medical research methodology 2004;4():6.
-
2004: Rosell Rafael; Danenberg Kathleen D; Alberola Vincente; Bepler Gerold; Sanchez Jose Javier; Camps Carlos; Provencio Mariano; Isla Dolores; Taron Miquel; Diz Pilar; Artal Angel;
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1318-25.
-
2003: Font Albert; Sánchez José Miguel; Tarón Miquel; Martinez-Balibrea Eva; Sánchez José Javier; Manzano José Luis; Margelí Mireia; Richardet Martin; Barnadas Agustí; Abad Albert; Rosell Rafael
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Investigational new drugs 2003;21(4):435-43.
-
2003: Rosell Rafael; Taron Miquel; Camps Carlos; López-Vivanco Guillermo
Influence of genetic markers on survival in non-small cell lung cancer.
Drugs of today (Barcelona, Spain : 1998) 2003;39(10):775-86.
-
2003: Felip E; Rosell R; Domine M; Santomé L; Garrido P; Font A; Carrato A; Terrasa J; Vadell C; Mañe J M; Baselga J;
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(10):1549-54.
-
2003: Balaña C; Manzano J-L; Moreno I; Cirauqui B; Abad A; Font A; Mate J-L; Rosell R
A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(9):1425-9.
-
2003: Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba J L; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez J J; de las Peñas R; Felip E; López-Vivanco G;
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3207-13.
-
2003: Rosell Rafael; Crino Lucio; Danenberg Kathleen; Scagliotti Giorgio; Bepler Gerold; Taron Miquel; Alberola Vicente; Provencio Mariano; Camps Carlos; De Marinis Filippo; Sanchez Jose Javier; Peñas Ramon
Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
Seminars in oncology 2003;30(4 Suppl 10):19-25.
-
2003: Rosell Rafael; Taron Miquel; Alberola Vicente; Massuti Bartomeu; Felip Enriqueta
Genetic testing for chemotherapy in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S97-102.
-
2003: Rosell Rafael; Taron Miguel; Barnadas Agusti; Scagliotti Giorgio; Sarries Carme; Roig Barbara
Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.
Cancer control : journal of the Moffitt Cancer Center 2003;10(4):297-305.
-
2003: Ramirez Jose Luis; Sarries Carme; de Castro Pedro Lopez; Roig Barbara; Queralt Cristina; Escuin Daniel; de Aguirre Itziar; Sanchez Jose Miguel; Manzano Jose Luis; Margelí Mireia; Sanchez Jose Javier; Astudillo Julio; Taron Miquel; Rosell Rafael
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.
Cancer letters 2003;193(2):207-16.
-
2003: Balaña Carme; Ramirez Jose Luis; Taron Miquel; Roussos Yannis; Ariza Aurelio; Ballester Rosa; Sarries Carme; Mendez Pedro; Sanchez Jose Javier; Rosell Rafael
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1461-8.
-
2003: Cardenal F; Domine M; Massutí B; Carrato A; Felip E; Garrido P; Juan O; Artal A; Barneto I; López-Vivanco G; Balcells M; Rosell R
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
Lung cancer (Amsterdam, Netherlands) 2003;39(2):201-7.
-
2003: Camps Carlos; Sarries Carmen; Roig Bárbara; Sanchez José Javier; Queralt Cristina; Sancho Eva; Martinez Natividad; Tarón Miguel; Rosell Rafael
Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients.
Clinical lung cancer 2003;4(4):237-41.
-
2003: Ramirez J L; Taron M; Balaña C; Sarries C; Mendez P; de Aguirre I; Nuñez L; Roig B; Queralt C; Botia M; Rosell R
Serum DNA as a tool for cancer patient management.
Roczniki Akademii Medycznej w Bialymstoku (1995) 2003;48():34-41.
-
2002: Sánchez José Miguel; Balañá Carme; Font Albert; Sánchez José Javier; Manzano José Luis; Guillot Mónica; Margelí Mireia; Richardet Martin; Rosell Rafael
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2002;38(3):309-15.
-
2002: Rosell Rafael; Lord Reginald V N; Taron Miquel; Reguart Noemi
DNA repair and cisplatin resistance in non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2002;38(3):217-27.
-
2002: Sarries Carme; Haura Eric B; Roig Barbara; Taron Miquel; Abad Albert; Scagliotti Giorgio; Rosell Rafael
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.
Pharmacogenomics 2002;3(6):763-80.
-
2002: Rosell Rafael; Tarón Miquel; Sarries Carme; Queralt Cristina; Roig Barbara
Beta-tubulin mutational analysis: tantalizing findings.
Lung cancer (Amsterdam, Netherlands) 2002;38(1):99-100.
-
2002: Vallejos V; Balaña C; Fraile M; Roussos Y; Capellades J; Cuadras P; Ballester R; Ley A; Arellano A; Rosell R
Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas.
Journal of neuro-oncology 2002;59(1):81-90.
-
2002: Ramírez de Molina Ana; Rodríguez-González Agustín; Gutiérrez Ruth; Martínez-Piñeiro Luis; Sánchez José; Bonilla Félix; Rosell Rafael; Lacal Juan
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers.
Biochemical and biophysical research communications 2002;296(3):580-3.
-
2002: Font A; Sanchez J M; Rosell R; Taron M; Martinez E; Guillot M; Manzano J L; Margeli M; Barnadas A; Abad A
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Lung cancer (Amsterdam, Netherlands) 2002;37(2):213-8.
-
2002: Lord Reginald V N; Brabender Jan; Gandara David; Alberola Vicente; Camps Carlos; Domine Manuel; Cardenal Felip; Sánchez José M; Gumerlock Paul H; Tarón Miquel; Sánchez José J; Danenberg Kathleen D; Danenberg Peter V; Rosell Rafael
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2286-91.
-
2002: Monzo Mariano; Taron Miquel; Rosell Rafael
Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.
Journal of the National Cancer Institute 2002;94(10):774-6; author reply 777.
-
2002: Fischer J R; Baas P; Becker H D; Chyczewski L; Dienemann H; Drings P; Ebert W; Herth F; Hoffmann H; Laudanski J; Lahm H; Manegold Ch; Monzó M; Mooi W J; Muley T; Neuner A; Niklinski J; Niklinska W; Rosell R; Taron M; van't Veer L; Werle B; Zandwijk N v
Report from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001.
Lung cancer (Amsterdam, Netherlands) 2002;36(2):221-4.
-
2002: Rosell Rafael; Crinó Lucio
Pemetrexed combination therapy in the treatment of non-small cell lung cancer.
Seminars in oncology 2002;29(2 Suppl 5):23-9.
-
2002: Felip Enriqueta; Rosell Rafael
Neoadjuvant chemotherapy in non-small cell lung cancer.
Current medicinal chemistry 2002;9(8):893-8.
-
2002: Rosell Rafael; Monzo Mariano; O'Brate Aurora; Taron Miquel
Translational oncogenomics: toward rational therapeutic decision-making.
Current opinion in oncology 2002;14(2):171-9.
-
2002: Rosell Rafael; Monzó Mariano; Alberola Vicente; Taron Miquel; Barnadas Agustin; Sánchez Jose Miguel; Manzano Jose Luis; Sanchez José Javier
Determinants of response and resistance to cytotoxics.
Seminars in oncology 2002;29(1 Suppl 4):110-8.
-
2001: Rosell R; Felip E; Maestre J; Sanchez J M; Sanchez J J; Manzano J L; Astudillo J; Taron M; Monzo M
The role of chemotherapy in early non-small-cell lung cancer management.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 3():S63-74.
-
2001: Monzo M; Rosell R; Taron M
Drug resistance in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 2():S91-4.
-
2001: Rosell R; Saijo N
Meeting Report of the Seventh IASLC Lung Cancer Biology Workshop: Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer, Barcelona, Spain, April 30- May 3, 2001.
Lung cancer (Amsterdam, Netherlands) 2001;34(3):465-6.
-
2001: Rosell R; Felip E
Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.
Seminars in oncology 2001;28(4 Suppl 14):37-44.
-
2001: Font A; Abad A; Monzó M; Sanchez J J; Guillot M; Manzano J L; Piñol M; Ojanguren I; Rosell R
Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer.
Diseases of the colon and rectum 2001;44(4):549-57.
-
2001: Rosell R; Sánchez J M; Tarón M; O'Brate A; Gutiérrez J L; Monzó M; Felip E; Sánchez J J; Alberola V
Novel approaches in the treatment of non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2001;15(3 Suppl 6):52-60.
-
2001: Rosell R; Tarón M; O'Brate A
Predictive molecular markers in non-small cell lung cancer.
Current opinion in oncology 2001;13(2):101-9.
-
2001: Rosell R; Green M; Gumerlock P
Advances in the treatment of non-small cell lung cancer: molecular markers take the stage.
Seminars in oncology 2001;28(1 Suppl 2):28-34.
-
2001: Isla D; Rosell R; Sánchez J J; Carrato A; Felip E; Camps C; Artal A; González-Larriba J L; Azagra P; Alberola V; Martin C; Massutí B;
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1071-7.
-
2000: Maurel J; Martinez-Trufero J; Artal A; Martin C; Puertolas T; Zorrrilla M; Herrero A; Antón A; Rosell R
Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2000;30(2):107-16.
-
2000: Felip E; Rosell R; Alberola V; Gómez-Codina J; Maestre J; Astudillo J; Camps C; Gonzalez-Larriba J L; Moreno I; Paredes A; Artal A; García-Gómez R; Garrido P; Cardenal F; Barneto I; Sánchez J J
Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial.
Clinical lung cancer 2000;1(4):287-93.
-
2000: Sacristán J A; Kennedy-Martin T; Rosell R; Cardenal F; Antón A; Lomas M; Alberola V; Massuti B; Carrato A; Minshall M
Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2000;28(2):97-107.
-
2000: O'Brate A; Tarón M; Gandara D; Rosell R
Sharing new approaches to translational research in non-small cell lung cancer.
The oncologist 2000;5(6):514-9.
-
1999: Escuín D; Rosell R
The anti-apoptosis survivin gene and its role in human cancer: an overview.
Clinical lung cancer 1999;1(2):138-43.
-
1999: Rosell R; Gómez-Codina J; Camps C; Javier Sánchez J; Maestre J; Padilla J; Cantó A; Abad A; Roig J
Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial.
Lung cancer (Amsterdam, Netherlands) 1999;26(1):7-14.
-
1999: Monzó M; Rosell R; Felip E; Astudillo J; Sánchez J J; Maestre J; Martín C; Font A; Barnadas A; Abad A
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2100-4.
-
1999: Rosell R; Calvo R; Sánchez J J; Maurel J; Guillot M; Monzó M; Núñez L; Barnadas A
Genetic susceptibility associated with rare HRAS1 variable number of tandem repeats alleles in Spanish non-small cell lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1849-54.
-
1999: Monzó M; Rosell R; Sánchez J J; Lee J S; O'Brate A; González-Larriba J L; Alberola V; Lorenzo J C; Núñez L; Ro J Y; Martín C
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1786-93.
-
1999: Rosell R
New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations.
Seminars in oncology 1999;26(3 Suppl 11):32-7.
-
1999: Rosell R
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: recent results and future developments.
Seminars in oncology 1999;26(3 Suppl 11):1-3.
-
1999: Font A; Moyano A J; Puerto J M; Tres A; Garcia-Giron C; Barneto I; Anton A; Sanchez J J; Salvador A; Rosell R
Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
Cancer 1999;85(4):855-63.
-
1999: Cardenal F; López-Cabrerizo M P; Antón A; Alberola V; Massuti B; Carrato A; Barneto I; Lomas M; García M; Lianes P; Montalar J; Vadell C; González-Larriba J L; Nguyen B; Artal A; Rosell R
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):12-8.
-
1999: Rosell R; Martin C; Balaña C
Ifosfamide in non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 5():S25-8.
-
1998: Antón A; Díaz-Fernández N; González Larriba J L; Vadell C; Masutti B; Montalar J; Barneto I; Artal A; Rosell R
Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
Lung cancer (Amsterdam, Netherlands) 1998;22(2):139-48.
-
1998: Felip E; Massuti B; Camps C; Benito D; Isla D; González-Larriba J L; López-Cabrerizo M P; Salamanca O; Puerto-Pica J; Moyano A; Baselga J; Rosell R
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2723-8.
-
1998: Rosell R; Tonato M; Sandler A
The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
Seminars in oncology 1998;25(4 Suppl 9):27-34.
-
1998: Calvo R; Pifarré A; Rosell R; Sánchez J J; Monzó M; Ribera J M; Feliu E
H-RAS 1 minisatellite rare alleles: a genetic susceptibility and prognostic factor for non-Hodgkin's lymphoma.
Journal of the National Cancer Institute 1998;90(14):1095-8.
-
1998: Rosell R
The integration of newer agents into neoadjuvant therapy.
Seminars in oncology 1998;25(3 Suppl 8):24-7.
-
1998: Martínez-López E; Abad A; Font A; Monzó M; Ojanguren I; Pifarré A; Sánchez J J; Martín C; Rosell R
Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer.
Gastroenterology 1998;114(6):1180-7.
-
1998: Aldea A I; Barnadas A; Tarrats A; Vaquero M; Muñoz C; Krugger M; Monzó M; Rosell R
[Analysis of telomeric length in epithelial carcinoma of the ovary]
Medicina clínica 1998;110(15):561-5.
-
1998: Sánchez-Céspedes M; Monzó M; Rosell R; Pifarré A; Calvo R; López-Cabrerizo M P; Astudillo J
Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):113-6.
-
1997: de Anta J M; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández J J; Moreno I; Sánchez-Céspedes M
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
Oncogene 1997;15(24):2951-8.
-
1997: Rosell R; Pifarré A
[Clinical usefulness of the study of genomic lesions in solid tumors]
Medicina clínica 1997;109(17):664-6.
-
1997: Rosell R; López Cabrerizo M P; Maurel J; Calvo R; Martín C; Martínez Roca M
[Positron emission tomography detection of residual disease in a case of lung cancer]
Medicina clínica 1997;109(16):629-31.
-
1997: Rosell R; Felip E; Massuti B; González-Larriba J L; Benito D; López-Cabrerizo M P; Salamanca O; Camps C; Puerto-Pica J
A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 12):S12-56-S12-60.
-
1997: Graus F; Dalmou J; Reñé R; Tora M; Malats N; Verschuuren J J; Cardenal F; Viñolas N; Garcia del Muro J; Vadell C; Mason W P; Rosell R; Posner J B; Real F X
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(8):2866-72.
-
1997: Sánchez-Céspedes M; Rosell R; Pifarré A; López-Cabrerizo M P; Barnadas A; Sánchez J J; Lorenzo J C; Abad A; Monzó M; Navas-Palacios J J
Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(7):1229-35.
-
1997: Carrato A; Rosell R; Camps C; Antón A; García-Gómez R; Aranda E; Massutí B; Díaz-Fernández N; Sánchez J J; García-Paredes M L
Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1997;17(2-3):261-9.
-
1997: Rosell R; Pifarré A; Monzó M; Astudillo J; López-Cabrerizo M P; Calvo R; Moreno I; Sanchez-Céspedes M; Font A; Navas-Palacios J J
Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors.
International journal of cancer. Journal international du cancer 1997;74(3):330-4.
-
1997: Sánchez Céspedes M; López Cabrerizo M P; Moreno I; Ariza A; Monzó M; Rosell R
[Significance of heterozygosity loss in the long arm of chromosome 5 (5q21) in small cell carcinoma of the lung]
Medicina clínica 1997;109(1):1-5.
-
1997: Rosell R; López-Cabrerizo M P; Astudillo J
Preoperative chemotherapy for stage IIIA non-small cell lung cancer.
Current opinion in oncology 1997;9(2):149-55.
-
1997: Rosenfeld M R; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real F X; Posner J B; Dalmau J
Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.
Journal of the National Cancer Institute 1997;89(5):381-5.
-
1997: Pifarré A; Rosell R; Monzó M; De Anta J M; Moreno I; Sánchez J J; Ariza A; Mate J L; Martinez E; Sánchez M
Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer.
British journal of cancer 1997;75(2):184-9.
-
1996: Maurel J; Rosell R; Lorenzo J C
Poor prognosis Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET).
Cancer treatment reviews 1996;22(6):425-36.
-
1996: Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez J J; Moreno I; Maurel J; López M P; Abad A; de Anta J M
Molecular staging of non-small cell lung cancer according to K-ras genotypes.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):1083-6.
-
1996: Rosell R; Font A; Pifarré A; Canela M; Maurel J; Arellano A; Izquierdo J
The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC.
Chest 1996;109(5 Suppl):102S-106S.
-
1996: Casado A; Rosell R; García-Gómez R; Díaz-Rubio E; Pérez-Manga G; Font A; Benavides A; Martín M
Phase II study of mitonafide in non-small cell lung cancer (NSCLC).
Investigational new drugs 1996;14(4):415-7.
-
1995: Ariza A; Mate J L; Isamat M; López D; Von Uexküll-Güldeband C; Rosell R; Fernández-Vasalo A; Navas-Palacios J J
Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type.
The Journal of pathology 1995;177(4):363-8.
-
1995: Rosell R; González-Larriba J L; Alberola V; Molina F; Monzó M; Benito D; Pérez J M; de Anta J M
Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Seminars in oncology 1995;22(6 Suppl 14):12-8.
-
1995: Rosell R; Molina F; Moreno I; Martínez E; Pifarré A; Font A; Li S; Skacel Z; Gómez-Codina J; Camps C
Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S59-70.
-
1995: Abad A; Garcia P; Gravalos C; Tusquets I; Font A; Perez G; Cortés-Funes H; Fabregat X; Barnadas A; Rosell R
Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
Cancer 1995;75(6):1238-44.
-
1995: Alberola V; Rosell R; González-Larriba J L; Molina F; Ayala F; García-Conde J; Benito D; Pérez J M
Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 3():S49-52.
-
1995: Rosell R; Monzo M; Molina F; Martinez E; Pifarre A; Moreno I; Mate J L; de Anta J M; Sanchez M; Font A
K-ras genotypes and prognosis in non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 3():S15-20.
-
1994: Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas J J; Monzo M
K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
Lung cancer (Amsterdam, Netherlands) 1994;11(1-2):19-27.
-
1994: Rosell R; Maestre J; Font A; Moreno I; Molina F; Milla A; Gómez-Codina J; Camps C
A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer.
Seminars in oncology 1994;21(3 Suppl 4):28-33.
-
1994: Rosell R; Gómez-Codina J; Anton A; Sánchez J J; Vadell C
Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate.
Seminars in oncology 1994;21(1 Suppl 1):48-53.
-
1994: Rosell R; Gómez-Codina J; Camps C; Maestre J; Padille J; Cantó A; Mate J L; Li S; Roig J; Olazábal A
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
The New England journal of medicine 1994;330(3):153-8.
-
1993: Carles J; Rosell R; Ariza A; Pellicer I; Sanchez J J; Fernandez-Vasalo G; Abad A; Barnadas A
Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1993;10(3-4):209-19.
-
1993: Rosell R; Li S; Skacel Z; Mate J L; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
Oncogene 1993;8(9):2407-12.
-
1993: Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A
LAS 30451: a novel 5-HT3 antagonist.
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 1():S33-4.
-
1992: Rosell R; Carles J; Abad A; Ribelles N; Barnadas A; Benavides A; Martin M
Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.
Investigational new drugs 1992;10(3):171-5.
-
1992: Rosell R; Carles J; Abad A; Jimeno J M; Moreno I; Barnadas A; Ribelles N; Haboubi N
Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer.
Investigational new drugs 1992;10(2):123-8.
-
1992: Moreno I; Rosell R; Abad A; Barnadas A; Carles J; Ribelles N; Solano V; Font A
Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1344-7.
-
1991: Abad A; Rosell R; Pastor M C; Barnadas A; Carles J; Ribelles N; Oller B; Armengol M; Salva A; Ribas M
Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?
American journal of clinical oncology 1991;14(5):393-6.
-
1991: Rosell R; Carles J; Ariza A; Moreno I; Ribelles N; Solano V; Pellicer I; Barnadas A; Abad A
A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer.
Cancer 1991;67(10):2448-53.
-
1991: Abad A; Rosell R; Barnadas A; Carles J; Ribelles N; Solano V
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(2):153.
-
1991: Diaz-Rubio E; Martin M; Rosell R; Valerdi J J; Gonzalez-Larriba J L; Barriga J J
The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial.
Acta oncologica (Stockholm, Sweden) 1991;30(3):339-42.
-
1991: Moreno I; Rosell R; Abad-Esteve A; Barnadas A; Carles J; Ribelles N
Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.
Oncology 1991;48(5):397-402.
-
1990: Rosell R; Moreno I; Maestre J; Olazabal A; Carles J; Barnadas A; Abad-Esteve A; Ribelles N; Canela M
Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: a meta-analytic review.
Journal of surgical oncology 1990;45(2):124-30.
-
1990: Rosell R; Millá F; Carles J; Batlle M; Ribelles N; Juncà J
[The description of a new cellular type, Pinocchio cells, induced during the treatment of solid tumors with interleukin-2]
Medicina clínica 1990;95(12):447-50.
-
1990: Díaz-Rubio E; González-Larriba J L; Rosell R; Abad A; Martín M; Valerdi J J; Barriga J J
Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(5):379-80.
-
1990: Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Cancer 1990;65(8):1692-9.
-
1989: Rosell R; Abad-Esteve A; Moreno I
[Value of substituted benzamides in controlling acute post-cisplatin emesis]
Medicina clínica 1989;93(19):756.
-
1989: Abad-Esteve A; Diaz-Rubio E; Jimeno J M; Rosell R; Villar A; Gonzalez-Larriba J L
Oral idarubicin in measurable gastric cancer.
American journal of clinical oncology 1989;12(1):14-6.
-
1989: Romeu J; Texidó A; Rosell R; Abad-Esteve A; Solans R; Carles J
[Carcinoma of unknown origin. Diagnostic study of 48 cases and its clinical yield]
Medicina clínica 1989;92(6):201-6.
-
1989: Abad-Esteve A; Rosell R; Moreno I; Serichol M; Moya L; Ribas-Mundo M
Antiemetic efficacy of escalating doses of alizapride against chemotherapy-induced emesis.
Oncology 1989;46(4):235-7.
-
1989: Fernandez C; Rosell R; Abad-Esteve A; Monras P; Moreno I; Serichol M; Roviralta M
Quality of life during chemotherapy in non-small cell lung cancer patients.
Acta oncologica (Stockholm, Sweden) 1989;28(1):29-33.
-
1988: Abad-Esteve A; Rosell R; Moreno I; Fernández-Marcial C; Roselló M; Ribas Mundó M
[VP-16, vincristine, adriamycin and cyclophosphamide (EVAC) in patients with small-cell lung cancer]
Medicina clínica 1988;90(14):569-72.
-
1987: Rosell R; Abad-Esteve A; Morera J; Monras P; Moreno I; Ruiz J; Fernandez C; Ribas-Mundo M
A randomized study comparing platinum, doxorubicin, and VP-16 with platinum, 4'-epidoxorubicin, and VP-16 in patients with non-small-cell lung cancer.
American journal of clinical oncology 1987;10(3):245-8.
-
1987: Rosell R; Abad-Esteve A; Ribas-Mundó M; Moreno I; Fernández-Marcial C
[Effectiveness of high-dose metoclopramide in the control of acute emesis induced by chemotherapy]
Medicina clínica 1987;88(10):434.
-
1986: Abad-Esteve A; Rosell R; Moreno I; Monrás P; Fernández C; Serichol M; Clotet M; Ribas Mundó M
[Evaluation of an antiemetic regimen with a high-dose metoclopramide, dexamethasone and diphenhydramine combination in chemotherapy regimens with cisplatin]
Medicina clínica 1986;87(19):796-8.
-
1985: Rosell R; Abad-Esteve A; Ribas-Mundo M; Moreno I
Evaluation of a combination antiemetic regimen including iv high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens.
Cancer treatment reports 1985;69(7-8):909-10.
Sign-in to see more
